Treatment-Resistant Depression: What is the role of Ketamine, DBS, VNS, TMS, and Psychedelics? Special Guest Dr. Scott Aaronson

New Perceptions

English - June 24, 2020 20:00 - 59 minutes - 67.8 MB
Medicine Health & Fitness Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Evolution of Depression Management: Where have we been? Where are we going? And what role will Psychedelics play? Special Guest Dr. Alan Schatzberg

Next Episode: The Neuroscience Behind Psychedelics with Special Guest Dr. Josh Siegel.

Join the Editors of The Journal of Psychedelic Psychiatry as they discuss Treatment-Resistant Depression with Special Guest and Psychiatrist Dr. Scott Aaronson.

Dr. Scott Aaronson obtained his M.D. from Harvard University in 1981. He is currently an Associate Professor at The University of Maryland School of Medicine, a Distinguished Life Fellow of the American Psychiatric Association, a Fellow of The American College of Psychiatrists. He serves on the board of the American Society of Clinical Psychopharmacology and the board of the Clinical TMS Society. He currently is the Director of Clinical Research for The Retreat at Sheppard Pratt.

Referenced Articles on Treatment-Resistant Depression:

https://www.ncbi.nlm.nih.gov/pubmed/30974339

https://journals.sagepub.com/doi/abs/10.1177/0004867418808585?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=anpa

Website: https://www.journalofpsychedelicpsychiatry.org/

Twitter: https://twitter.com/psychedelic_org

Facebook: https://www.facebook.com/JournalofPsychedelicPsychiatry/

Instagram: https://www.instagram.com/journalpsychedelicpsychiatry/

---

Support this podcast: https://podcasters.spotify.com/pod/show/journalofpsychedelic/support

Twitter Mentions

@psychedelic_org